Shimoli Barot, MD, highlights the role of maintenance palbociclib plus trastuzumab, pertuzumab, and endocrine therapy in HER2-positive breast cancer.
Shimoli Barot, MD
Advertisement
Shimoli Barot, MD, is of Cleveland Clinic
Articles by Shimoli Barot, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Advisory Committee to Weigh RP1 Plus Nivolumab in Anti–PD-1–Pretreated Advanced Melanoma
3
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
4
FDA Awards Orphan Drug Designation to Enzomenib for ALL
5